Pfizer/Protalix’s Elelyso Offers Gaucher Patients A Vegetarian Option
Executive Summary
Gaucher disease enzyme-replacement therapy Elelyso is the first FDA-approved plant-cell based recombinant therapeutic protein, a biosimilar option that may eliminate the production-related problems Genzyme’s Cerezyme and Shire’s Vpriv face with animal cell-based processes. Pfizer is launching Elelyso at a 25% discount to Cerezyme and promising to maintain a two-year supply.
You may also be interested in...
Pfizer Rare Disease Leaders: An Interview With “The Pink Sheet” DAILY
Pfizer’s rare disease commercial unit head Andrew Callos and research unit chief scientific officer Kevin Lee outline how the company’s rare disease business has grown since formed in 2010, discuss why the Big Pharma’s interest in drugs for rare diseases is here to stay and consider what’s next for the portfolio on the business development front.
EMA Orphan Approval Path Seems More Twisty After Pfizer/Protalix’s Elelyso Stumbles
The European Medicines Agency will not recommend Pfizer/Protalix’s Elelyso for type 1 Gaucher, maintaining that it is too similar to Shire’s Vpriv, despite the firms’ argument that their product offers better bone marrow data and alleviates shortage concerns.
The Orphan Drug Bubble
Two former biotech high flyers are up for sale, with Amylin attracting more would-be suitors than Human Genome Sciences. The spectacle of the bidding is great. But did you know that the orphan drug company Alexion is worth more than those two companies combined?